Tetraphase Pharmaceuticals, Inc. (TTPH)

[Schnauzer1]

If we are lucky the cUTI P3 will include arm evaluating IV to pill transition, as this is one of the major efficacy benefits of eravacycline. Chief science officer indicated this might be possibility at last conference call. I would expect to see more on this point as P1 of oral pill formulation unfolds in next few months! The data they need to understand is the volume of medicine in pill needed to produce efficacious results (volume of ingestion to blood volume). Also there is a significant food effect, understanding this more fully will be important!